JP7065854B2 - ミトコンドリア機能障害に関連する疾患を治療するための化合物 - Google Patents

ミトコンドリア機能障害に関連する疾患を治療するための化合物 Download PDF

Info

Publication number
JP7065854B2
JP7065854B2 JP2019532202A JP2019532202A JP7065854B2 JP 7065854 B2 JP7065854 B2 JP 7065854B2 JP 2019532202 A JP2019532202 A JP 2019532202A JP 2019532202 A JP2019532202 A JP 2019532202A JP 7065854 B2 JP7065854 B2 JP 7065854B2
Authority
JP
Japan
Prior art keywords
group
compound
carbon atoms
formula
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019532202A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526634A (ja
JP2019526634A5 (OSRAM
Inventor
アントワーヌ ダンシャン，
アグニェシカ セコウスカ，
パトリス ギャルニエ，
Original Assignee
エーエムエーバイオティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーエムエーバイオティクス filed Critical エーエムエーバイオティクス
Publication of JP2019526634A publication Critical patent/JP2019526634A/ja
Publication of JP2019526634A5 publication Critical patent/JP2019526634A5/ja
Application granted granted Critical
Publication of JP7065854B2 publication Critical patent/JP7065854B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019532202A 2016-08-30 2017-08-30 ミトコンドリア機能障害に関連する疾患を治療するための化合物 Active JP7065854B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306094.0 2016-08-30
EP16306094.0A EP3290039B1 (en) 2016-08-30 2016-08-30 Compounds for treating diseases associated with a mitochondrial dysfonction
PCT/EP2017/071812 WO2018041919A1 (en) 2016-08-30 2017-08-30 Compounds for treating diseases associated with a mitochondrial dysfonction

Publications (3)

Publication Number Publication Date
JP2019526634A JP2019526634A (ja) 2019-09-19
JP2019526634A5 JP2019526634A5 (OSRAM) 2020-10-01
JP7065854B2 true JP7065854B2 (ja) 2022-05-12

Family

ID=56896495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019532202A Active JP7065854B2 (ja) 2016-08-30 2017-08-30 ミトコンドリア機能障害に関連する疾患を治療するための化合物

Country Status (15)

Country Link
US (2) US10857135B2 (OSRAM)
EP (2) EP3290039B1 (OSRAM)
JP (1) JP7065854B2 (OSRAM)
KR (1) KR20200011927A (OSRAM)
CN (1) CN110035758B (OSRAM)
AU (1) AU2017317651B2 (OSRAM)
BR (1) BR112019004236A2 (OSRAM)
CA (1) CA3034694A1 (OSRAM)
ES (1) ES2800917T3 (OSRAM)
MA (1) MA46099A (OSRAM)
MX (1) MX394782B (OSRAM)
RU (1) RU2019108824A (OSRAM)
SG (1) SG11201901689YA (OSRAM)
WO (1) WO2018041919A1 (OSRAM)
ZA (1) ZA201900997B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3290039B1 (en) * 2016-08-30 2020-03-25 Amabiotics Compounds for treating diseases associated with a mitochondrial dysfonction
US20210052589A1 (en) * 2018-03-07 2021-02-25 Amabiotics Compounds for treating alzheimer's disease
CA3126424A1 (en) * 2019-01-29 2020-08-06 Holobiome, Inc. Methods and compositions for treating and preventing cns disorders and other conditions caused by gut microbial dysbiosis
US20230040247A1 (en) * 2019-09-12 2023-02-09 Amabiotics Compounds for treating neurodegenerative diseases
WO2021048431A1 (en) * 2019-09-12 2021-03-18 Amabiotics Compounds for treating ataxia
CN116850191A (zh) * 2023-06-16 2023-10-10 山东大学齐鲁医院 奎因在制备治疗线粒体功能障碍相关疾病药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936615A (ja) * 1982-08-24 1984-02-28 Takeda Chem Ind Ltd 発がん予防剤
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
EP1221615A2 (en) * 1995-04-25 2002-07-10 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
FR3002139B1 (fr) * 2013-02-21 2015-06-19 Amabiotics Utilisation cosmetique de la queuine
GB201417163D0 (en) * 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
EP3290039B1 (en) * 2016-08-30 2020-03-25 Amabiotics Compounds for treating diseases associated with a mitochondrial dysfonction

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Biosci. Rep.，2008年，Vol.28，pp.73-81
Biosci. Rep.，2010年，Vol.30，pp.135-148
Cancer Biology & Therapy，2008年，Vol.7, No.1，pp.85-91
Environmental and Molecular Mutagenesis，2010年，Vol.51，pp.391-405
Mitochondrion，2004年，Vol.4，pp.755-762

Also Published As

Publication number Publication date
CN110035758A (zh) 2019-07-19
SG11201901689YA (en) 2019-03-28
RU2019108824A (ru) 2020-10-01
BR112019004236A2 (pt) 2019-05-28
ES2800917T3 (es) 2021-01-05
EP3290039A1 (en) 2018-03-07
RU2019108824A3 (OSRAM) 2020-12-31
JP2019526634A (ja) 2019-09-19
US20190224174A1 (en) 2019-07-25
US11684611B2 (en) 2023-06-27
AU2017317651A1 (en) 2019-03-07
CA3034694A1 (en) 2018-03-08
US20210046056A1 (en) 2021-02-18
MX2019002369A (es) 2019-11-07
CN110035758B (zh) 2023-06-16
WO2018041919A1 (en) 2018-03-08
US10857135B2 (en) 2020-12-08
MX394782B (es) 2025-03-24
KR20200011927A (ko) 2020-02-04
AU2017317651B2 (en) 2022-12-15
EP3290039B1 (en) 2020-03-25
ZA201900997B (en) 2020-05-27
MA46099A (fr) 2019-07-10
EP3506903A1 (en) 2019-07-10

Similar Documents

Publication Publication Date Title
JP7065854B2 (ja) ミトコンドリア機能障害に関連する疾患を治療するための化合物
EP2581440B1 (en) Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
JP2022033788A (ja) ソベチロム誘導体
Liu et al. The parthenolide derivative ACT001 synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson’s disease in mice
Anashkina et al. Molecular mechanisms of aberrant neuroplasticity in autism spectrum disorders
MD3680243T2 (ro) Compus pentaciclic
US20120083464A1 (en) Neuroprotective properties of 5'-methylthioadenosine
Zhang et al. Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets
US11235006B2 (en) Inhibiting or alleviating agent for Aβ-induced damage
Edalatmanesh et al. Valproic acid-mediated inhibition of trimethyltin-induced deficits in memory and learning in the rat does not directly depend on its anti-oxidant properties
US20210052589A1 (en) Compounds for treating alzheimer's disease
US20230040247A1 (en) Compounds for treating neurodegenerative diseases
US20200093782A1 (en) Ariants of 2-[6-(4-chlorophenoxy)hexyl]-oxirane-2-carboxylic acid for use in the treatment, prevention and/or amelioration of brain diseases
Zhang The inflammatory injury in the striatal microglia-dopaminergic
HK40072665A (en) Inhibiting or alleviating agent for a beta-induced damage
Chaudhari et al. NEURODEGENRATIVE DISORDERS: CURRENT STATUS AND FUTURE PROSPECTIVE

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200824

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220426

R150 Certificate of patent or registration of utility model

Ref document number: 7065854

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250